Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03225664 | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced | active not recruiting | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 |
| clinicaltrials |
| NCT06060613 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors(Agni-01) | recruiting | Phase 1 / Phase 2 | 208 | Obsidian Therapeutics, Inc.INDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 / Phase 3 | 230 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07306624 | Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer | recruiting | Phase 2 | 62 | STCube, Inc.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04922658 | Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 76 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05652686 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | recruiting | Phase 1 / Phase 2 | 203 | Phanes TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05800015 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 160 | Regeneron PharmaceuticalsINDUSTRY | 10 | Jul 15, 2026 | clinicaltrials |
| NCT07405190 | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | recruiting | Phase 2 | 46 | Massachusetts General HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07450183 | Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 | not yet recruiting | Phase 2 | 33 | Henry Ford Health SystemOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07669779 | A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 348 | AkesoINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703228 | Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC | active not recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07355205 | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer(FLINN) | recruiting | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07452224 | ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 80 | iLeukon Therapeutics, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05937906 | Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.(IMMUNOMEK) | recruiting | Phase 1 / Phase 2 | 24 | Centre Georges Francois LeclercOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment(DeLLphi-307) | active not recruiting | Phase 2 | 32 | AmgenINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 262 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05003037 | Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 106 | Li Zhang, MDOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05543330 | A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | recruiting | Phase 1 / Phase 2 | 116 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients(MERLIN) | recruiting | Phase 2 | 37 | Fundación GECPOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07314216 | Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma | recruiting | Phase 2 | 15 | Hunan Cancer HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06268210 | Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(NeoLazer) | active not recruiting | Phase 2 | 160 | Yonsei UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06552234 | Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC(REPOROS) | recruiting | Phase 2 | 30 | Centre Hospitalier Intercommunal de Toulon La Seyne sur MerOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06940401 | JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations | active not recruiting | Phase 1 / Phase 2 | 44 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07518160 | JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study | recruiting | Phase 2 | 35 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688577 | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Xilio Development, Inc.INDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT04745689 | Study of AZD2811 + Durvalumab in ES-SCLC(TAZMAN) | active not recruiting | Phase 2 | 31 | AstraZenecaINDUSTRY | 4 | Jul 6, 2026 | clinicaltrials |
| NCT05887492 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 126 | Tango Therapeutics, Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | Phase 2 | 39 | Asrar AlahmadiOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07538804 | A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 294 | Avistone Biotechnology Co., Ltd.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07685197 | Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC | not yet recruiting | Phase 2 | 100 | Zhou ChengzhiOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT05785767 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 / Phase 3 | 149 | Regeneron PharmaceuticalsINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy(COSTAR Lung) | active not recruiting | Phase 2 / Phase 3 | 758 | GlaxoSmithKlineINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT05118854 | A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05443126 | A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | recruiting | Phase 1 / Phase 2 | 265 | Ellipses PharmaINDUSTRY | 8 | Jul 1, 2026 | clinicaltrials |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)(LIBRA) | recruiting | Phase 2 | 278 | AstraZenecaINDUSTRY | 12 | Jul 1, 2026 | clinicaltrials |
| NCT07609121 | Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC | recruiting | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2026source: clinicaltrials